Osimertinib Achieves Primary PFS Endpoint in Phase III LAURA Trial for Unresectable Stage III EGFR-Mutated NSCLC

Feb 20, 2024 08:04 CST Updated 08:04

AstraZeneca

Biopharmaceutical Manufacturer

On February 19, AstraZeneca announced that in the Phase III study codenamed LAURA, Tagrisso (osimertinib) showed results compared to placebo.) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable stage III, epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) following concurrent chemoradiotherapy (CRT).

Although the overall survival (OS) data were not yet mature at the time of this analysis, a favorable trend for Tagrisso has already been observed.The trial willContinue withOSEvaluated as a key secondary endpoint.

It is estimated that 2.4 million people worldwide are diagnosed with lung cancer each year, of which 80%-85% are diagnosed with non-small cell lung cancer. Approximately 10%-15%BeautyChina and EuropeEGFR mutations are present in NSCLC patients and in 30%-40% of Asian patients. More than 1/6 of NSCLC patients are diagnosed with unresectable stage III disease (15%).

"These results represent a significant advance in the treatment of Stage III EGFR-mutated lung cancer, a disease with a high tendency for early progression and spread to the brain, and for which there are currently no targeted therapies," said Suresh Ramalingam, MD, Executive Director of the Winship Cancer Institute at Emory University in Atlanta and principal investigator of the trial. "The LAURA study demonstrates,Osimertinib"It can provide effective clinical benefits and may become the first targeted treatment option for patients with Stage III disease."

At the same time, in the previous two days, based on Phase IIIPositive results from the FLAURA2 study,OsimertinibNew Indication Approved by FDA, used forFirst-line combination chemotherapy for patients withEGFR MutationPatients with non-small cell lung cancer (NSCLC).

Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.

Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.